<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Tanaffos</journal-id><journal-id journal-id-type="iso-abbrev">Tanaffos</journal-id><journal-id journal-id-type="publisher-id">Tanaffos</journal-id><journal-title-group><journal-title>Tanaffos</journal-title></journal-title-group><issn pub-type="ppub">1735-0344</issn><issn pub-type="epub">2345-3729</issn><publisher><publisher-name>National Research Institute of Tuberculosis and Lung Disease</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25191397</article-id><article-id pub-id-type="pmc">4153178</article-id><article-id pub-id-type="publisher-id">Tanaffos-11-026</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nicolini</surname><given-names>Antonello</given-names></name></contrib></contrib-group><aff>Division of Respiratory Diseases, Hospital of Sestri Levante, Genoa-ITALY</aff><author-notes><corresp id="cor1">Correspondence to: Nicolini A, Address: Pulmonary Rehabilitation Unit Hospital of Sestri Levante, Genoa, Italy. Email address: <email xlink:href="antonello.nicolini@gmail.com">antonello.nicolini@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><year>2012</year></pub-date><volume>11</volume><issue>1</issue><fpage>26</fpage><lpage>31</lpage><history><date date-type="received"><day>26</day><month>7</month><year>2011</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 National Research Institute of Tuberculosis and Lung Disease</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><sec id="st1"><title>Background</title><p>The results of bronchodilator therapy in chronic obstructive pulmonary disease (COPD) are not satisfactory and because of this, many drugs are administered for treatment of disease. We examined the short-term additive bronchodilator effects of tiotropium in patients with stable COPD already treated with salmeterol twice daily.</p></sec><sec id="st2"><title>Materials and Methods</title><p>In a double-blind, double-dummy randomized study we evaluated the acute bronchodilator efficacy of a single 18 &#x000b5;g dose of tiotropium in patients with COPD under chronic treatment with a long acting beta-adrenergic (salmeterol 50&#x000b5;g twice a day). Measurements of forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and six-minute walking test (6 MWT) as indicator of daily activities were made before and after giving the drug. A total of 129 outpatients with stable COPD (Gold level 2 -3- 4) were enrolled and 92 completed the study.</p></sec><sec id="st3"><title>Results</title><p>Tiotropium elicited a significantly greater bronchodilation than the placebo. The action of the drug was elicited as increase in FEV1 (p &#x02264; 0.001) and FVC (p &#x02264; 0.001); 6-MWT increased 35 meters in patients treated with tiotropium compared to 2.5 meters in those receiving placebo (p &#x02264; 0.001).</p></sec><sec id="st4"><title>Conclusion</title><p>Addition of tiotropium to chronic administration of a beta-adrenergic drug such as salmeterol induced an increase in pulmonary function parameters and in exercise capacity suggesting that association of the two drugs can be more efficient for treatment of disease and improvement of daily living activities than beta-adrenergics alone.</p></sec></abstract><kwd-group><kwd>Chronic obstructive pulmonary disease</kwd><kwd>Pulmonary function</kwd><kwd>Six-minute walk test</kwd><kwd>Tiotropium</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S0001"><title>INTRODUCTION</title><p>Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease that can be defined as a pathologic illness characterized by a progressive reduction of respiratory function (<xref rid="CIT0001" ref-type="bibr">1</xref>). The flow-limitation of COPD is due to the reduction of the calibre of the respiratory airways caused by the contraction of smooth bronchial muscles and by the reduction of pulmonary elasticity leading to pulmonary hyperinflation (<xref rid="CIT0002" ref-type="bibr">2</xref>).</p><p>Spirometry; therefore, is the most important test in the diagnosis and staging of COPD. The functional parameters such as forced expiratory volume (FEV 1), forced vital capacity (FVC), slow vital capacity (SVC) and inspiratory capacity (IC) are the simplest parameters to evaluate the gravity of the disease (<xref rid="CIT0003" ref-type="bibr">3</xref>). FVC, SVC and IC can provide some indirect information about hyperinflation, a very important indicator of severity of the symptoms and are highly correlated with the degree of dyspnea (<xref rid="CIT0004" ref-type="bibr">4</xref>).</p><p>Pharmacological therapy can actually reduce dyspnea and improve exercise tolerance (<xref rid="CIT0005" ref-type="bibr">5</xref>). In addition to beta-adrenergic drugs, newer anticholinergic drugs have been recently introduced. These drugs block muscarinic receptors for acetylcholine in the airways, and thus produce a reduction in vagal tone (<xref rid="CIT0003" ref-type="bibr">3</xref>).</p><p>Five subtypes of human muscarinic receptors have been discovered (from M1 to M5), but in the airways only three subtypes appear (M1, M2, M3). M1 and M3 receptors are stimulated by acetylcholine with the cholinergic effect of bronchoconstriction, while M2 receptors inhibit the release of acetylcholine producing an inhibitory feedback on bronchoconstriction (<xref rid="CIT0003" ref-type="bibr">3</xref>). Tiotropium is a potent and highly specific competitive antagonist especially for M1 and M3 receptors (<xref rid="CIT0006" ref-type="bibr">6</xref>). Based on several studies it appears that in patients with COPD tiotropium can significantly reduce the level of dyspnea (<xref rid="CIT0007" ref-type="bibr">7</xref>), improve the quality of life (<xref rid="CIT0007" ref-type="bibr">7</xref>), and improve the parameters of hyperinflation such as IC, FRC, RV (<xref rid="CIT0008" ref-type="bibr">8</xref>) and exercise tolerance (<xref rid="CIT0009" ref-type="bibr">9</xref>). Several short and long term studies on tiotropium have shown an improvement in respiratory function tests greater than with ipratropium (<xref rid="CIT0010" ref-type="bibr">10</xref>) or with salmeterol twice daily (<xref rid="CIT0011" ref-type="bibr">11</xref>).</p><p>Some studies have recently been published, showing the possibility of augmenting the bronchodilator efficacy in patients with COPD by using the combination of tiotropium with a long-acting beta-adrenergic such as salmeterol (<xref rid="CIT0012" ref-type="bibr">12</xref>) or formoterol (<xref rid="CIT0013" ref-type="bibr">13</xref>, <xref rid="CIT0014" ref-type="bibr">14</xref>). The effects observed were faster and greater using the combination of two drugs instead of tiotropium only. We examined the short-term additive bronchodilator effects of tiotropium in patients with stable COPD already treated with salmeterol twice daily.</p></sec><sec sec-type="materials|methods" id="S0002"><title>MATERIALS AND METHODS</title><sec id="S20003"><title>Aim of the study</title><p>This study aimed to determine if a single dose of 18 &#x000b5;g of tiotropium bromide was associated with an improvement in morning lung function and tolerance of daily exercise test. The study took place at the Pulmonary Rehabilitation Unit of General Hospital of Sestri Levante, Italy from January 2006 to April 2008.</p></sec><sec id="S20004"><title>b) Inclusion and exclusion criteria</title><p>The study groups consisted of 129 outpatients (79 males, 50 females), with a mean age of 67.3 yrs. and stable COPD. There were 55 level 2 GOLD, 50 level 3 GOLD and 24 level 4 GOLD patients (<xref rid="CIT0015" ref-type="bibr">15</xref>). Eligible participants were all adults, had no exacerbation in the last 60 days, had FEV 1 &#x02264; 60% of predicted value, scored between 2 to 4 on the Modified Medical Research Council (MMRC) dyspnea questionnaire, and had been treated with salmeterol alone (50 &#x000b5;g twice a day) for more than three months.</p><p>Exclusion criteria were: history of a respiratory allergic disease; a coexisting cardiovascular or pulmonary disease and/or an orthopedic or cognitive impairment that prevented them from performing pulmonary function testing, 6-minute walk test (6 MWT) or from completing the questionnaire.</p><p>The characteristics and the subdivision of patients are illustrated in <xref ref-type="table" rid="T0001">Table 1</xref> and the patients&#x02019; flow-chart in <xref ref-type="fig" rid="F0001">Figure 1</xref>.
</p><fig id="F0001" position="float"><label>Figure 1</label><caption><p>Patients &#x02018; flow chart</p></caption><graphic xlink:href="Tanaffos-11-026-g001"/></fig><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Enrolled patients&#x02019; demographics and baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">TIOTROPIUM PATIENTS</th><th align="center" rowspan="1" colspan="1">PLACEBO PATIENTS</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of patients</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">Average age (yrs.)</td><td align="center" rowspan="1" colspan="1">69.58&#x000b1;7.81</td><td align="center" rowspan="1" colspan="1">67.11&#x000b1;5.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex(males%)</td><td align="center" rowspan="1" colspan="1">70,0%</td><td align="center" rowspan="1" colspan="1">66,0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Smokers</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">Ex-smokers</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV 1 (ml) <xref ref-type="table-fn" rid="TF0001">*</xref>
</td><td align="center" rowspan="1" colspan="1">1110&#x000b1;419.0</td><td align="center" rowspan="1" colspan="1">868&#x000b1;0,72</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV1% predicted <xref ref-type="table-fn" rid="TF0001">*</xref>
</td><td align="center" rowspan="1" colspan="1">55.6&#x000b1;6.82</td><td align="center" rowspan="1" colspan="1">56.9&#x000b1;7.18</td></tr><tr><td align="left" rowspan="1" colspan="1">FVC (ml) <xref ref-type="table-fn" rid="TF0001">*</xref>
</td><td align="center" rowspan="1" colspan="1">2290&#x000b1;735.7</td><td align="center" rowspan="1" colspan="1">1926&#x000b1;570.6</td></tr><tr><td align="left" rowspan="1" colspan="1">FVC% predicted<xref ref-type="table-fn" rid="TF0001">*</xref>
</td><td align="center" rowspan="1" colspan="1">64.8&#x000b1;7,96</td><td align="center" rowspan="1" colspan="1">65.3&#x000b1;6.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Tiffeneau Index <xref ref-type="table-fn" rid="TF0001">*</xref> (T.I.)</td><td align="center" rowspan="1" colspan="1">51.84&#x000b1;9.56</td><td align="center" rowspan="1" colspan="1">44.86&#x000b1;8.63</td></tr><tr><td align="left" rowspan="1" colspan="1">6-Minute Walk Test (meters)</td><td align="center" rowspan="1" colspan="1">165&#x000b1;65</td><td align="center" rowspan="1" colspan="1">193&#x000b1;79</td></tr><tr><td align="left" rowspan="1" colspan="1">MMRC<xref ref-type="table-fn" rid="TF0002">**</xref>
</td><td align="center" rowspan="1" colspan="1">3.0&#x000b1;0.8</td><td align="center" rowspan="1" colspan="1">2.9&#x000b1;0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">BODE Index</td><td align="center" rowspan="1" colspan="1">6.27&#x000b1;1.51</td><td align="center" rowspan="1" colspan="1">6.32&#x000b1;2.39</td></tr></tbody></table><table-wrap-foot><fn id="TF0001"><label>*</label><p>Post-bronchodilator value</p></fn><fn id="TF0002"><label>**</label><p>Modified Medical Research Council Dyspnea Scale</p></fn></table-wrap-foot></table-wrap><p>The study was carried out according to the rules of the &#x0201c;Declaration of Helsinki&#x0201d;; the local ethics committee approved our study. All patients provided written informed consent before beginning the study.</p></sec><sec id="S20005"><title>b) Protocol</title><p>The study was performed using a double-blind, double-dummy randomised design. Patients received a single dose of 18 &#x000b5;g of tiotropium bromide dry powder capsules delivered via the Handihaler or a single dose of placebo delivered via the Handihaler. For allocation of the participants a computer-generated list of random numbers was used. To avoid any bias, single dose of each drug was given to patients by different nurses. The nurses did not know which drug the patient received.</p><p>All treatments were administered at the same time (between 8 and 9 a.m.).</p><p>Consumption of cola drinks, coffee or tea was avoided 6 hours before administering the drug and during the investigation.</p></sec><sec id="S20006"><title>c) Functional measurements</title><p>On test day measurements of FVC, FEV1 and Tiffeneau index (T.I.) were recorded one hour before and one hour after administering the drug. Spirometric examinations were conducted three times (according to ERS/ATS standard) (<xref rid="CIT0016" ref-type="bibr">16</xref>) and the results of the best FVC and FEV1 of three exams were considered in the subsequent analysis. For the measurements we used Cosmed PFT 4 spirometer (Rome, Italy).</p><p>A six minute walk test (according to ATS guidelines) (<xref rid="CIT0017" ref-type="bibr">17</xref>) was performed one hour before and one hour after the administration of drug. At the beginning and at the end of each six minute walk test the degree of dyspnea (Borg scale), pulse, respiratory rate and SpO<sub>2</sub> were determined.</p></sec><sec id="S20007"><title>d) Statistical analysis</title><p>Spirometric data (FVC, FEV1 and TI) and the 6 MWT results were analyzed using the Student's t-test for paired variables. A probability level of p &#x02264; 0.05 was considered significant for all tests.</p></sec></sec><sec sec-type="results" id="S0008"><title>RESULTS</title><p>One hundred twenty-nine patients were enrolled and 100 were randomized. Twenty-nine patients were excluded because of concurrent cardiovascular disease. Fifty patients were allocated to inhalation of 18&#x000b5;g tiotropium bromide and fifty were allocated to inhalation of placebo. Ninety-two patients completed the study. Eight patients refused to repeat the six minute-walk test. The changes in FVC 1 hour after administration of tiotropium were greater than those induced by placebo (an increase of 170&#x000b1;10.76 ml versus no increase induced by placebo) and the difference was statistically significant (p&#x02264; 0.001).</p><p>Also, the changes in FEV1 1 hour after administering tiotropium were significantly greater than those induced by placebo (an increase of 132&#x000b1;0.430 compared to no increase induced by placebo) (p&#x02264; 0.001) (<xref ref-type="fig" rid="F0002">Figure 2</xref> and <xref ref-type="fig" rid="F0003">3</xref>). Tiotropium induced a small improvement in Tiffeneau index greater than placebo, but the difference between the two treatments was not statistically significant (p &#x02264; 0.148). The changes in six minute-walk test distance 1 hour after administration of tiotropium were greater than those induced by placebo (an increase of 35.50 meters induced by tiotropium compared with 2,50 meters induced by placebo) and this difference was statistically significant (p &#x02264; 0.001, <xref ref-type="fig" rid="F0004">Figure 4</xref>).</p><fig id="F0002" position="float"><label>Figure 2</label><caption><p>Median changes in FEV1 (ml) before the administration of tiotropium (group 1) and placebo (group 2) and after the administration of tiotropium and placebo (p&#x0003c; 0.001)</p></caption><graphic xlink:href="Tanaffos-11-026-g002"/></fig><fig id="F0003" position="float"><label>Figure 3</label><caption><p>Median changes in FEV1 (ml) before the administration of tiotropium (group 1) and placebo (group 2) and after the administration of tiotropium and placebo (p &#x0003c; 0.001).</p></caption><graphic xlink:href="Tanaffos-11-026-g003"/></fig><fig id="F0004" position="float"><label>Figure 4</label><caption><p>Median changes in 6 MWT (meters) before the administration of tiotropium (group 1) and placebo (group 2) and after the administration of tiotropium and placebo (p &#x0003c; 0.001).</p></caption><graphic xlink:href="Tanaffos-11-026-g004"/></fig><p>The average values of FVC, FEV1 and 6 MWT before and after administration of drugs and p-values are reported in <xref ref-type="table" rid="T0002">Table 2</xref>.
</p><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Changes in FVC, FEV1 and 6 MWT before and 1 hour after the administration of tiotropium or placebo (p &#x02264; 0.001)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Tiotropium</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">FVC before drug(ml)</td><td align="center" rowspan="1" colspan="1">2120&#x000b1;627,5</td><td align="center" rowspan="1" colspan="1">1821&#x000b1;492</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">FVC after drug(ml)</td><td align="center" rowspan="1" colspan="1">2290&#x000b1;735,5</td><td align="center" rowspan="1" colspan="1">1798&#x000b1;88</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">FEV1 before drug(ml)</td><td align="center" rowspan="1" colspan="1">1110&#x000b1;419</td><td align="center" rowspan="1" colspan="1">866,5&#x000b1;273,5</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">FEV1 after drug (ml)</td><td align="center" rowspan="1" colspan="1">1232&#x000b1;462</td><td align="center" rowspan="1" colspan="1">808&#x000b1;308</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">6MWT before drug (meters)</td><td align="center" rowspan="1" colspan="1">320&#x000b1;165</td><td align="center" rowspan="1" colspan="1">320&#x000b1;193</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">6MWT after drug (meters)</td><td align="center" rowspan="1" colspan="1">350&#x000b1;200</td><td align="center" rowspan="1" colspan="1">330&#x000b1;196</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Difference after drug</bold>
<break/>
<bold>- before drug</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Average</bold>
<break/>
<bold>Tiotropium</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Average</bold>
<break/>
<bold>Placebo</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>p value</bold>
<break/>
<bold>(t-student)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FVC (ml)</td><td align="center" rowspan="1" colspan="1">167.2 &#x000b1; 197.7</td><td align="center" rowspan="1" colspan="1">- 106.4 &#x000b1; 237.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV1 (ml)</td><td align="center" rowspan="1" colspan="1">120.4 &#x000b1; 96.7</td><td align="center" rowspan="1" colspan="1">- 42.4 &#x000b1; 67.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">6MWT (meters)</td><td align="center" rowspan="1" colspan="1">34.7 &#x000b1; 32.9</td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1; 8.6</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion" id="S0009"><title>DISCUSSION</title><p>Bronchodilation may be achieved either by stimulating adrenergic receptors or by inhibiting muscarinic receptors. These two different mechanisms of action (<xref rid="CIT0018" ref-type="bibr">18</xref>), both are associated with improvement of dyspnea, functional parameters, exercise tolerance and quality of life (<xref rid="CIT0008" ref-type="bibr">8</xref>, <xref rid="CIT0011" ref-type="bibr">11</xref>, <xref rid="CIT0015" ref-type="bibr">15</xref>).</p><p>A recent paper has revised the idea of reversibility in COPD (<xref rid="CIT0019" ref-type="bibr">19</xref>). An average increase in FEV1 after administering a short-acting bronchodilator occurs in the majority of patients, approximately 100-130 ml and this parameter is smaller than the threshold of 200 ml which is clinically considered significant (<xref rid="CIT0019" ref-type="bibr">19</xref>). Like residual functional capacity and inspiratory capacity (<xref rid="CIT0008" ref-type="bibr">8</xref>), forced vital capacity can also be an important indicator of bronchodilation. This is a parameter of respiratory function that has not been sufficiently appreciated. The increase of vital capacity indicates a larger moving volume of air and a reduction of air trapping. Thus, a bronchodilator can produce reduction of dyspnea and an improvement in exercise tolerance (<xref rid="CIT0020" ref-type="bibr">20</xref>). Another study has shown that therapy with both tiotropium and budesonide/formoterol produces significant improvements in morning lung function, morning symptoms, as well as in patients&#x02019; ability to perform morning activities. This signifies an improvement in health-related quality of life (<xref rid="CIT0021" ref-type="bibr">21</xref>).</p><p>Our study aimed to reproduce real-life conditions and was done to determine whether or not a short-term functional improvement (an increase in patients&#x02019; ability to perform activities of daily living) obtained by adding tiotropium is superior to the use of salmeterol alone. The obtained results, increased FEV1 (&#x02265; 120 ml) and FVC (&#x02265; 170 ml), demonstrate that an inhalation of a single dose of 18 &#x000b5;g of tiotropium produces an improvement in expiratory volume and a reduction in hyperinflation (<xref rid="CIT0019" ref-type="bibr">19</xref>, <xref rid="CIT0020" ref-type="bibr">20</xref>) over and above that produced by salmeterol alone. In addition, there was a significant improvement in distance covered during the six-minute walk test.</p><p>In conclusion, this study demonstrates that adding tiotropium to salmeterol produces not only a greater bronchodilation than placebo in patients previously treated with a beta-adrenergic drug alone, as suggested by previous authors (<xref rid="CIT0022" ref-type="bibr">22</xref>&#x02013;<xref rid="CIT0024" ref-type="bibr">24</xref>), but also improves exercise tolerance and the ability to perform morning daily living activities.</p></sec></body><back><ack><title>Acknowledgments</title><p>The author would like to thank Dr. Maura Ferrari Bravo for his assistance in statistical analyses and Dr. Cornelius Barlascini, for reviewing the manuscript.</p></ack><sec id="S0010"><title>Conflict of Interest</title><p>This study was carried out independently from manufacturers and the author has no conflict of interest to declare.</p></sec><ref-list><title>REFERENCES</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodder</surname><given-names>R</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name><name><surname>Menjoge</surname><given-names>S</given-names></name><name><surname>Viel</surname><given-names>K</given-names></name></person-group><article-title>Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2007</year><volume>2</volume><issue>2</issue><fpage>157</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">18044688</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anzueto</surname><given-names>A</given-names></name></person-group><article-title>Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions</article-title><source>Am J Med</source><year>2006</year><volume>119</volume><issue>10 Suppl 1</issue><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16996899</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>New development in anticholinergic drugs</article-title><source>Eur Respir Rev</source><year>1996</year><volume>6</volume><fpage>290</fpage><lpage>4</lpage></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name></person-group><article-title>The importance of spirometry in COPD and asthma: effect on approach to management</article-title><source><italic>Chest</italic></source><year>2000</year><volume>117</volume><issue>2 Suppl</issue><fpage>15S</fpage><lpage>9S</lpage><pub-id pub-id-type="pmid">10673468</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>DE</given-names></name><name><surname>Revill</surname><given-names>SM</given-names></name><name><surname>Webb</surname><given-names>KA</given-names></name></person-group><article-title>Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><issue>5</issue><fpage>770</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11549531</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Disse</surname><given-names>B</given-names></name><name><surname>Witek</surname><given-names>TJ</given-names><suffix>JR</suffix></name></person-group><person-group person-group-type="editor"><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Anticholinergics: tiotropium</article-title><source>Progress in respiratory research</source><year>2000</year><volume>31</volume><publisher-loc>London</publisher-loc><publisher-name>Karger</publisher-name><comment>New drugs for asthma, allergy and COPD</comment></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincken</surname><given-names>W</given-names></name><name><surname>van Noord</surname><given-names>JA</given-names></name><name><surname>Greefhorst</surname><given-names>AP</given-names></name><name><surname>Bantje</surname><given-names>TA</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name><name><surname>Korducki</surname><given-names>L</given-names></name><etal/></person-group><article-title>Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium</article-title><source>Eur Respir J</source><year>2002</year><volume>19</volume><issue>2</issue><fpage>209</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11871363</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>ZuWallack</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name></person-group><article-title>Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes</article-title><source>Chest</source><year>2003</year><volume>124</volume><issue>5</issue><fpage>1743</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14605043</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maltais</surname><given-names>F</given-names></name><name><surname>Hamilton</surname><given-names>A</given-names></name><name><surname>Marciniuk</surname><given-names>D</given-names></name><name><surname>Hernandez</surname><given-names>P</given-names></name><name><surname>Sciurba</surname><given-names>FC</given-names></name><name><surname>Richter</surname><given-names>K</given-names></name><etal/></person-group><article-title>Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD</article-title><source>Chest</source><year>2005</year><volume>128</volume><issue>3</issue><fpage>1168</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">16162703</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Noord</surname><given-names>JA</given-names></name><name><surname>Bantje</surname><given-names>TA</given-names></name><name><surname>Eland</surname><given-names>ME</given-names></name><name><surname>Korducki</surname><given-names>L</given-names></name><name><surname>Cornelissen</surname><given-names>PJ</given-names></name></person-group><article-title>A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group</article-title><source>Thorax</source><year>2000</year><volume>55</volume><issue>4</issue><fpage>289</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">10722768</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusasco</surname><given-names>V</given-names></name><name><surname>Hodder</surname><given-names>R</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Korducki</surname><given-names>L</given-names></name><name><surname>Towse</surname><given-names>L</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name></person-group><article-title>Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD</article-title><source>Thorax</source><year>2003</year><volume>58</volume><issue>5</issue><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">12728159</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Centanni</surname><given-names>S</given-names></name><name><surname>Santus</surname><given-names>P</given-names></name><name><surname>Verga</surname><given-names>M</given-names></name><name><surname>Mondoni</surname><given-names>M</given-names></name><name><surname>di Marco</surname><given-names>F</given-names></name><etal/></person-group><article-title>The functional impact of adding salmeterol and tiotropium in patients with stable COPD</article-title><source>Respir Med</source><year>2004</year><volume>98</volume><issue>12</issue><fpage>1214</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15588043</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Noord</surname><given-names>JA</given-names></name><name><surname>Aumann</surname><given-names>JL</given-names></name><name><surname>Janssens</surname><given-names>E</given-names></name><name><surname>Smeets</surname><given-names>JJ</given-names></name><name><surname>Verhaert</surname><given-names>J</given-names></name><name><surname>Disse</surname><given-names>B</given-names></name><etal/></person-group><article-title>Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD</article-title><source>Eur Respir J</source><year>2005</year><volume>26</volume><issue>2</issue><fpage>214</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">16055868</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Di Marco</surname><given-names>F</given-names></name><name><surname>Santus</surname><given-names>P</given-names></name><name><surname>Boveri</surname><given-names>B</given-names></name><name><surname>Verga</surname><given-names>M</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name><etal/></person-group><article-title>The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD</article-title><source>Pulm Pharmacol Ther</source><year>2004</year><volume>17</volume><issue>1</issue><fpage>35</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14643169</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusasco</surname><given-names>V</given-names></name><name><surname>Crapo</surname><given-names>R</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name></person-group><article-title>ATS/ERS Task Forces standardisation of lung function testing</article-title><source>Eur Resp J</source><year>2005</year><volume>26</volume><fpage>319</fpage><lpage>38</lpage></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Jenkins</surname><given-names>CR</given-names></name><name><surname>Hurd</surname><given-names>SS</given-names></name></person-group><article-title>GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><issue>5</issue><fpage>1256</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11316667</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><collab>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories</collab><article-title>ATS statement: guidelines for the six-minute walk test</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><issue>1</issue><fpage>111</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12091180</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerveri</surname><given-names>I</given-names></name><name><surname>Ansaldo</surname><given-names>E</given-names></name></person-group><article-title>Effects of tiotropium on pulmonary function Italian Review of Respiratory Disease</article-title><year>2008</year><volume>23</volume><issue>suppl 23</issue><fpage>5</fpage><lpage>9</lpage></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soriano</surname><given-names>JB</given-names></name><name><surname>Mannino</surname><given-names>DM</given-names></name></person-group><article-title>Reversing concepts on COPD irreversibility</article-title><source>Eur Respir J</source><year>2008</year><volume>31</volume><issue>4</issue><fpage>695</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18378779</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>A</given-names></name></person-group><article-title>Tiotropium: a drug for COPD Italian Review of Respiratory Dis</article-title><year>2008</year><volume>23</volume><issue>suppl 23</issue><fpage>28</fpage><lpage>30</lpage></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welte</surname><given-names>T</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>G</given-names></name><name><surname>Peterson</surname><given-names>S</given-names></name><name><surname>Polanowski</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>180</volume><issue>8</issue><fpage>741</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">19644045</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Noord</surname><given-names>JA</given-names></name><name><surname>Aumann</surname><given-names>JL</given-names></name><name><surname>Janssens</surname><given-names>E</given-names></name><name><surname>Verhaert</surname><given-names>J</given-names></name><name><surname>Smeets</surname><given-names>JJ</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD</article-title><source>Chest</source><year>2006</year><volume>129</volume><issue>3</issue><fpage>509</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">16537846</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>And&#x000f2;</surname><given-names>F</given-names></name><name><surname>Santus</surname><given-names>P</given-names></name><name><surname>Ruggeri</surname><given-names>P</given-names></name><name><surname>Di Marco</surname><given-names>F</given-names></name><name><surname>Sanduzzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD</article-title><source>Pulm Pharmacol Ther</source><year>2007</year><volume>20</volume><issue>5</issue><fpage>556</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">16914336</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perng</surname><given-names>DW</given-names></name><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Su</surname><given-names>KC</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Perng</surname><given-names>RP</given-names></name><name><surname>Tao</surname><given-names>CW</given-names></name></person-group><article-title>Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids</article-title><source>Respirology</source><year>2006</year><volume>11</volume><issue>5</issue><fpage>598</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">16916333</pub-id></element-citation></ref></ref-list></back></article>